Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bartnik, M.
Right arrow Articles by Rydén, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bartnik, M.
Right arrow Articles by Rydén, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Diabetes and the heart: compromised myocardial function — a common challenge

M. Bartnik1, K. Malmberg and L. Rydén

Department of Cardiology, Karolinska Hospital, Stockholm, Sweden

1 Malgorzata Bartnik MD, Department of Cardiology, Karolinska Hospital, 171 76 Stockholm, Sweden.

Abstract

The increasing comorbidity of diabetes and congestive heart failure becomes a new challenge for cardiological care. Although diabetic cardiomyopathy shows no unique morphological features, profound alterations are found at the biochemical level. Hyperglycaemia induces maladaptive mechanisms that can interfere with efficacy of cardiac energy metabolism, contractile myofibril function, and excitation-contraction coupling, resulting in cytoskeletal changes and increased neurohormonal activity. Metabolic conditions can induce cardiac remodelling and mechanisms acting in a vicious circle within which heart failure and insulin resistance contribute to each other. The currently available therapies and the future perspectives for management focused on metabolic targets, are reviewed.

Key Words: Diabetes mellitus • heart failure • myocardial metabolism • prognosis • treatment

References

  1. King H, Aubert RE, Herman WH. Global burden of diabetes 1995–2025. Prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414–1431[Abstract]
  2. Kanters SD, Banga JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a metaanalysis. Vasc Med. 1999;4:67–75[Abstract/Free Full Text]
  3. Laakso M, Lehto S. Epidemiology of macrovascular disease in diabetes. Diabetes Rev. 1997;5:294–315
  4. EUROASPIRE 11 Group. Lifestyle & risk factors management and use of drug therapies in coronary patients from 15 countries. Eur Heart J. 2001;22:554–572[Abstract/Free Full Text]
  5. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet. 2002;359:2140–2144[CrossRef][Web of Science][Medline]
  6. Reis SE, Holubkov R, Edmundowicz D, et al. Treatment of patients admitted to the hospital with congestive heart failure: speciality-related disparities in practice patterns and outcomes. J Am Coll Cardiol. 1997;30:733–738[Abstract]
  7. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22:6A–13A
  8. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72:S3–s9 (suppl)
  9. Cowie MR, Mosterd A, Wood D, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208–225[Free Full Text]
  10. Remme WJ, Swedberg K, ESC Task Force. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560[Free Full Text]
  11. Zannad F, Briancon S, Juilliere Y, et al, The EPICAL Investigators. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. J Am Coll Cardiol. 1999;33:734–742[Abstract/Free Full Text]
  12. Kitzman DW, Gardin JM, Gottdiener JS, et al. Cardiovascular Health Study Research Group. Importance of heart failure with preserved systolic function in patients =65 years of age. CHS Research Group. Cardiovascular Health Study. J Am Coll Cardiol. 2001;87:413–419
  13. Kannel WB. Need and prospects for prevention of cardiac failure. Eur J Clin Pharmacol. 1996;49(suppl 1):S3–S9
  14. The NETWORK investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J. 1998;19:481–489[Abstract/Free Full Text]
  15. The CONSENSUS trial study group. Effect of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987;316:1429–1435[Web of Science][Medline]
  16. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. 1999;100:1056–1064[Abstract/Free Full Text]
  17. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;214:2035–2038
  18. Amato L, Paolisso G, Cacciatore F, et alObservatorio Geriatrico Regione Campania Group. Congestive heart failure predicts the development of non-insulin dependent diabetes mellitus in the elderly. on behalf of theDiabetes Metab. 1997;23:213–218[Web of Science][Medline]
  19. Chae CU, Glynn RJ, Manson JE, Guralnik JM, Taylor JO, Pfeffer MA. Diabetes predicts congestive heart failure risk in the elderly. Circulation. 1998;98(suppl I):721
  20. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet. 2000;355:773–778[CrossRef][Web of Science][Medline]
  21. Suskin N, McKelvie RS, Rolueau J, Sigouin C, Wiecek E, Yusuf S. Increased insulin and glucose levels in heart failure. J Am Coll Cardiol. 1998;31(suppl A):249A
  22. Ärnlöv J, Lind L, Zethelius B, et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J. 2001;142:720–724[CrossRef][Web of Science][Medline]
  23. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver ME. Insulin resistance in chronic heart failure. Eur Heart J. 1994;15:1528–1532[Abstract/Free Full Text]
  24. Poole-wilson PA. Chronic heart failure: cause, pathophysiology, prognosis, clinical manifestations, investigations. Julian DG, Camm AJ, Fox KF, Hall RJC, Poole-Wilson PA. Diseases of the heart. London: Balliere-Tindall; 1989. p. 24–36
  25. Cohen-Solal A. Diastolic heart failure: myth or reality? Eur J Heart Fail. 2002;4:395–400[Free Full Text]
  26. Yu C-M, Lin H, Yang H, King S-L, Zhang Q, Lee SW-L. Progression of systolic abnormalities in patients with ‘isolated’ diastolic heart failure and diastolic dysfunction. Circulation. 2002;105:1195–1201[Abstract/Free Full Text]
  27. Cleland J. IMPROVEMENT of heart failure. AmsterdamPresented at the Annual Meeting of the European Society of Cardiology. 2000.
  28. Euro Heart Failure. StockholmReport at the Annual Congress of the European Society of Cardiology. 2001.
  29. Adams KF, Sueta CA, Gheorghiade M, et al. for the FIRST Investigators. Gender differences in survival in advanced heart failure. Insights from the FIRST Study. Circulation. 1999;99:1816–1821[Abstract/Free Full Text]
  30. Kalon KL, Andersson KM, Kannel WB, Grossman W, Levy D. Survival after onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107–115[Abstract/Free Full Text]
  31. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689–1694[Abstract/Free Full Text]
  32. Vasan RS, Iarson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol. 1999;33:1948–1955[Abstract/Free Full Text]
  33. Mosterd A, Cost B, Hoes AW, et al. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J. 2001;22:1318–1327[Abstract/Free Full Text]
  34. Stone P, Muller J, Hartwell T, et alMILIS Study group. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to adverse prognosis. for theJ Am Coll Cardiol. 1989;54:49–57
  35. Melchior T, Gadsboll P, Hildebrandt P, Kober L, Torp-Pedersen C. Clinical characteristics, left and right ventricular ejection fraction, and long term prognosis in patients with non-insulin dependent diabetes surviving an acute myocardial infarction. Diabet Med. 1996;13:450–456[CrossRef][Web of Science][Medline]
  36. McGuire DK, Emanuelsson H, Granger CB, et al, Gusto-IIb investigators. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. for theEur Heart J. 2000;21:1750–1758[Abstract/Free Full Text]
  37. Malmberg K, Rydén L, Efendic S. A randomized study of insulinglucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction: effects on 1-year mortality. J Am Coll Cardiol. 1995;26:57–65[Abstract]
  38. Bell DSH. Diabetic cardiomyopathy. A unique entity or a complication of coronary artery disease? Diabetes Care. 1995;18:708–714[Abstract]
  39. Dubrey SW, Raeveley DR, Seed M, et al. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes. 1994;43:831–835[Abstract]
  40. Zoneraich S, Mollura JL. Diabetes and the heart: state of the art in the 1990s. Can J Cardiol. 1993;9:293–299[Web of Science][Medline]
  41. Hardin N. The myocardial and vascular pathology of diabetic cardiomyopathy. Coron Artery Dis. 1996;7:99–108[Web of Science][Medline]
  42. Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol. 1995;18:301–305[Web of Science][Medline]
  43. UKPDS-35. Association of glycaemia with macrovascular and microvascular complication of type 2 diabetes: a prospective observational study. BMJ. 2000;321:405–412[Abstract/Free Full Text]
  44. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J. 2000;21:1368–1375[Abstract/Free Full Text]
  45. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001;103:2668–2673[Abstract/Free Full Text]
  46. Personage W, Hetmanski D, Cowley A. Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure. Am J Cardiol. 2002;89:696–703[CrossRef][Web of Science][Medline]
  47. Holzmann M, Olsson A, Johansson J, Jensen-Urstad M. Left ventricular diastolic function is related to glucose in a middle-aged population. J Intern Med. 2002;251:415–420[CrossRef][Web of Science][Medline]
  48. Braunwald E, Bristow R. Congestive heart failure: fifty years of progress. Circulation. 2000;102(suppl 4):14–23[Abstract/Free Full Text]
  49. Stanley WC. Metabolic dysfunction in the diabetic heart. Stanley WC, Rydén L. The diabetic coronary patient. London: Science Press Ltd; 1999. p. 13–28
  50. Taegtmeyer H, McNulty P, Young M. Adaptation and mal-adaptation of the heart in diabetes. Part I. Circulation. 2002;105:1727–1733[Free Full Text]
  51. King LM, Opie LH. Glucose delivery is a major determinant of glucose utilisation in the ischemic myocardium with a residual coronary flow. Cardiovasc Res. 1998;39:381–392[Abstract/Free Full Text]
  52. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose-fatty acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;13:785–789
  53. Young M, McNulty P, Taegtmeyer H. Adaptation and mal-adaptation of the heart in diabetes. Part II. Circulation. 2002;105:1861–1870[Free Full Text]
  54. Windt L, Cox K, Hofstra L, Doevendans P. Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease. Eur Heart J. 2001;23:774–787
  55. Way KJ, Katai N, King GL. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 2001;18:945–959[CrossRef][Web of Science][Medline]
  56. Xia P, Kramer RM, King GL. Identification of the mechanism for the inhibition of Na+, K+-adenosine triphosphatase by hyperglycaemia involving activation of protein kinase C and cytosolic phospholipase A2. J Clin Invest. 1995;96:733–740
  57. Alpert N, Mulieri L, Warshaw D. The failing human heart. Cardiovasc Res. 2002;54:1–10[Free Full Text]
  58. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol. 1995;27:169–179[Web of Science][Medline]
  59. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of incereased vascular superoxide production in human diabetes mellitus. Role of NADP(H) oxidase and endothelial nitric oxide synthase. Circulation. 2002;105:1656–1662[Abstract/Free Full Text]
  60. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med. 1991;325:293–302[Abstract]
  61. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–691[Abstract]
  62. Rydén L, Armstrong PW, Cleland JGF, et alATLAS Study Group. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. on behalf of theEur Heart J. 2000;21:1967–1978[Abstract/Free Full Text]
  63. Herings RMC, deBoer A, Stricker BHC, Leufkens HGM, Porsius A. Hypoglycemia associated with the use of inhibitors of angiotensin-converting enzyme. Lancet. 1996;345:1195–1198
  64. Morris AD, Boyle DIR, McMahon AD, et al. ACE inhibitor use is associated with hospitalisation for severe hypoglycemia in patients with diabetes. Diabetes Care. 1997;20:1363–1379[Abstract]
  65. Malmberg K, Herlitz J, Hjalmarsson , Rydén L. Effects on metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large scale studies. Eur Heart J. 1989;10:423–428[Abstract/Free Full Text]
  66. Bristow M, Gilbert EM, Abraham WT, et al. Effect of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomyopathy. Circulation. 1996;84:664 (suppl)
  67. Eichhorn EJ, Hesch CN, Barnett JH, et al. Effect on metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1994;24:1310–1320
  68. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation. 2001;103:2441–2446[Abstract/Free Full Text]
  69. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–1302[Abstract/Free Full Text]
  70. Bersin RM, Wolfe C, Kwasman M, et al. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroactetate. J Am Coll Cardiol. 1994;23:1617–1624[Abstract]
  71. Schmidt-Schweda St, Holubarsch Ch. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci. 2000;99:27–35[Medline]
  72. Szwed H, Sadowski Z, Pachocki R, et al. The anti-ischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-1. Cardiovasc Drugs Ther. 1999;13:217–222[CrossRef][Web of Science][Medline]
  73. Monti LD, Setola E, Palloshi A, et al. Metabolic and endothelial effects of trimetazidine in type 2 diabetic patients with ischemic dilated cardiomyopathy. [abstract 260]Diabetologia. 2001;44:68
  74. Blardi P, de Lalla A, Volpi L, Auteri A, Di Perri T. Increase of adenosine plasma levels after oral trimetazidine: a pharmacological preconditioning? Pharmacol Res. 2002;45:69–72[CrossRef][Web of Science][Medline]
  75. McMurray J, Pfeffer MA. New therapeutic options in congestive heart failure: part I. Circulation. 2002;105:2099–2106[Free Full Text]
  76. Malmberg K, Norhammar A, Wedel H, Rydén L. Glucometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocar dial infarction: long term results from the DIGAMI study. Circulation. 1999;99:2626–2632[Abstract/Free Full Text]
  77. Von Bibra H, Hansen A, Dounis V, Bystedt, Malmberg K, Rydén L. Diastolic myocardial function and myocardial microvasculature reserve improve with intense insulin treatment in type 2 diabetic patients. [abstract 265]Diabetologia. 2001;44:68
  78. Joslin EP. The treatment of diabetes mellitus. 3rd edition. London: H. Kimpton; 1924.
  79. Almbrand B, Johannesson B, Sjöstrand B, Malmberg K, Rydén L. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study. Eur Heart J. 2000;21:733–739[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Bartnik, M.
Right arrow Articles by Rydén, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Bartnik, M.
Right arrow Articles by Rydén, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?